Pulmonary Arterial Hypertension News and Research RSS Feed - Pulmonary Arterial Hypertension News and Research

Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
New report reveals prescription medication costs may increase up to 13% in 2016

New report reveals prescription medication costs may increase up to 13% in 2016

Prescription medication costs are expected to rise at least 11 percent, and possibly up to 13 percent, in 2016, according to a new report on national trends and projections in prescription drug expenditures. [More]
European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year. [More]
Circulating angiogenic factor shows PAH biomarker potential

Circulating angiogenic factor shows PAH biomarker potential

Hepatoma-derived growth factor predicts disease severity and survival in patients with pulmonary arterial hypertension, showing some possible clinical advantages over N-terminal pro-brain natriuretic peptide, researchers report. [More]
New blood test could help predict severity of pulmonary arterial hypertension

New blood test could help predict severity of pulmonary arterial hypertension

Johns Hopkins Medicine researchers report that rising blood levels of a protein called hematoma derived growth factor (HDGF) are linked to the increasing severity of pulmonary arterial hypertension, a form of damaging high blood pressure in the lungs. [More]
Potential non-invasive screening biomarker for SSc-PAH

Potential non-invasive screening biomarker for SSc-PAH

Serum asymmetric dimethylarginine may be an effective non-invasive screening biomarker for systemic sclerosis-related pulmonary arterial hypertension, study findings indicate. [More]
Right ventricular echocardiography predicts targeted therapy outcome in PAH

Right ventricular echocardiography predicts targeted therapy outcome in PAH

Echocardiography re-assessment of right ventricular function after targeted therapy is sufficient to predict subsequent prognosis in patients with pulmonary arterial hypertension, say researchers. [More]
Reduced RV functional reserve may explain poor SSc-PAH outcomes

Reduced RV functional reserve may explain poor SSc-PAH outcomes

Patients who develop pulmonary arterial hypertension as a consequence of systemic sclerosis have poorer right ventricular functional reserve than those with idiopathic disease, research published in Circulation shows. [More]
Elevated endothelial progenitor cells may characterise PAH patients

Elevated endothelial progenitor cells may characterise PAH patients

Plasma levels of endothelial progenitor cells are elevated in patients with pulmonary arterial hypertension, say researchers. [More]
Pulmonary hypertension impacts walking ability in SSc patients

Pulmonary hypertension impacts walking ability in SSc patients

The results of a meta-analysis show the adverse impact pulmonary hypertension has on the walking stamina of patients with systemic sclerosis. [More]

More evidence for combination therapy benefits in PAH

Another meta-analysis adds to evidence of increased benefits for patients with pulmonary arterial hypertension who are given combination therapy. [More]
Detailed digital models of human organs could bring substantial benefits to clinical trials

Detailed digital models of human organs could bring substantial benefits to clinical trials

Computer simulations of disease processes and detailed digital models of our organs could provide more accurate monitoring and outcome measurements for clinical trials, according to research being presented in Sheffield today. [More]
Novel gene therapy can treat pulmonary hypertension linked with heart failure

Novel gene therapy can treat pulmonary hypertension linked with heart failure

Scientists have used a novel gene therapy to halt the progression of pulmonary hypertension, a form of high blood pressure in the lung blood vessels that is linked to heart failure, according to a study led by Roger J. Hajjar, MD, Professor of Medicine and Director of the Cardiovascular Research Center at the Icahn School of Medicine at Mount Sinai. [More]
Meta-analysis supports combination therapy for PAH patients

Meta-analysis supports combination therapy for PAH patients

A meta-analysis shows that clinical worsening is significantly less likely in patients with pulmonary arterial hypertension if they are given combination treatment, rather than monotherapy. [More]
Minimally important dyspnoea, fatigue changes in PAH patients defined

Minimally important dyspnoea, fatigue changes in PAH patients defined

Researchers say that a change of around 1 unit in Borg dyspnoea or fatigue scores signifies an important change in patients with pulmonary arterial hypertension. [More]
Increased BMP7 levels predict PAH mortality

Increased BMP7 levels predict PAH mortality

Elevated levels of circulating bone morphogenetic protein 7 are associated with an increased mortality risk in patients with pulmonary arterial hypertension, find Chinese researchers. [More]
BMPR2 mutations affect outcomes of PAH patients

BMPR2 mutations affect outcomes of PAH patients

Mutations in the bone morphogenetic protein receptor type II gene affect not only the risk of developing pulmonary arterial hypertension but also the severity and outcomes of the disease, shows a meta-analysis of individual patient data. [More]

Tricuspid regurgitation tied to outcomes in PAH patients

Tricuspid regurgitation progresses in line with right ventricular remodelling and increasing pulmonary artery systolic pressure in patients with pulmonary arterial hypertension, research shows. [More]
Regulatory immune cells compromised in PAH

Regulatory immune cells compromised in PAH

Research suggests that regulatory T cells may play a part in all subtypes of pulmonary arterial hypertension. [More]
PAH role proposed for left heart failure biomarker

PAH role proposed for left heart failure biomarker

Levels of galectin-3 are elevated in patients with pulmonary arterial hypertension and correlate with disease severity, research shows. [More]
Left ventricular tissue phase mapping predicts PAH outcomes

Left ventricular tissue phase mapping predicts PAH outcomes

A tissue phase mapping study shows that left ventricular function is abnormal in patients with pulmonary arterial hypertension and is linked to clinical outcomes. [More]
Advertisement